Latest news and press releases about Indaptus Therapeutics, Inc. (INDP): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials.
Price
| Price | $3.21 |
| Market Cap | $364M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 32.78 |
| EV / EBITDA | -22.52 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -302.75% |
| Return on Invested Capital | -129.90% |
| Return on Assets | -128.66% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATXI · AZTR · GTBP · LIPO · NKGN · PBM · PTIX
Explore sector: Healthcare · Biotechnology
More sections of INDP: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks